vs

Side-by-side financial comparison of BigBear.ai Holdings, Inc. (BBAI) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $27.3M, roughly 1.4× BigBear.ai Holdings, Inc.). On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -37.7%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-22.1M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -9.2%).

BigBear.ai Holdings, Inc. develops and delivers artificial intelligence-powered decision support and analytics solutions. Its core offerings cover predictive analytics, supply chain optimization, and operational intelligence platforms, serving key segments including national defense, intelligence agencies, and commercial enterprise clients primarily across North America, helping customers improve operational efficiency and mitigate risks.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

BBAI vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.4× larger
GYRE
$37.2M
$27.3M
BBAI
Growing faster (revenue YoY)
GYRE
GYRE
+71.2% gap
GYRE
33.4%
-37.7%
BBAI
More free cash flow
GYRE
GYRE
$16.3M more FCF
GYRE
$-5.8M
$-22.1M
BBAI
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-9.2%
BBAI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BBAI
BBAI
GYRE
GYRE
Revenue
$27.3M
$37.2M
Net Profit
$-1.4M
Gross Margin
20.3%
95.3%
Operating Margin
-295.0%
0.3%
Net Margin
-3.7%
Revenue YoY
-37.7%
33.4%
Net Profit YoY
-340.1%
EPS (diluted)
$0.17
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBAI
BBAI
GYRE
GYRE
Q4 25
$27.3M
$37.2M
Q3 25
$33.1M
$30.6M
Q2 25
$32.5M
$26.8M
Q1 25
$34.8M
$22.1M
Q4 24
$43.8M
$27.9M
Q3 24
$41.5M
$25.5M
Q2 24
$39.8M
$25.2M
Q1 24
$33.1M
$27.2M
Net Profit
BBAI
BBAI
GYRE
GYRE
Q4 25
$-1.4M
Q3 25
$2.5M
$5.9M
Q2 25
$-228.6M
$1.6M
Q1 25
$-62.0M
$3.7M
Q4 24
$569.0K
Q3 24
$-15.1M
$2.9M
Q2 24
$-14.4M
$4.5M
Q1 24
$-127.8M
$9.9M
Gross Margin
BBAI
BBAI
GYRE
GYRE
Q4 25
20.3%
95.3%
Q3 25
22.4%
94.7%
Q2 25
25.0%
95.7%
Q1 25
21.3%
95.9%
Q4 24
37.4%
95.8%
Q3 24
25.9%
96.2%
Q2 24
27.8%
96.9%
Q1 24
21.1%
96.4%
Operating Margin
BBAI
BBAI
GYRE
GYRE
Q4 25
-295.0%
0.3%
Q3 25
-66.0%
22.7%
Q2 25
-278.1%
8.1%
Q1 25
-61.0%
10.3%
Q4 24
-18.6%
2.4%
Q3 24
-25.4%
16.6%
Q2 24
-41.9%
12.7%
Q1 24
-296.1%
29.7%
Net Margin
BBAI
BBAI
GYRE
GYRE
Q4 25
-3.7%
Q3 25
7.6%
19.4%
Q2 25
-704.0%
5.9%
Q1 25
-178.3%
16.9%
Q4 24
2.0%
Q3 24
-36.5%
11.2%
Q2 24
-36.3%
18.0%
Q1 24
-385.8%
36.6%
EPS (diluted)
BBAI
BBAI
GYRE
GYRE
Q4 25
$0.17
$-0.01
Q3 25
$-0.03
$0.03
Q2 25
$-0.71
$0.00
Q1 25
$-0.25
$0.00
Q4 24
$-0.47
$0.00
Q3 24
$-0.06
$0.01
Q2 24
$-0.06
$0.01
Q1 24
$-0.68
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBAI
BBAI
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$87.1M
$52.4M
Total DebtLower is stronger
$107.0M
Stockholders' EquityBook value
$611.9M
$106.0M
Total Assets
$894.5M
$166.1M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBAI
BBAI
GYRE
GYRE
Q4 25
$87.1M
$52.4M
Q3 25
$456.6M
$60.0M
Q2 25
$390.8M
$54.4M
Q1 25
$107.6M
$29.9M
Q4 24
$50.1M
$26.7M
Q3 24
$65.6M
$25.1M
Q2 24
$72.3M
$25.1M
Q1 24
$81.4M
$37.4M
Total Debt
BBAI
BBAI
GYRE
GYRE
Q4 25
$107.0M
Q3 25
$104.9M
Q2 25
$103.0M
Q1 25
$101.4M
Q4 24
$136.2M
Q3 24
$195.7M
Q2 24
$195.7M
Q1 24
$195.6M
Stockholders' Equity
BBAI
BBAI
GYRE
GYRE
Q4 25
$611.9M
$106.0M
Q3 25
$610.0M
$101.9M
Q2 25
$266.6M
$92.0M
Q1 25
$197.8M
$68.1M
Q4 24
$-3.7M
$63.3M
Q3 24
$127.5M
$63.2M
Q2 24
$134.7M
$60.4M
Q1 24
$143.2M
$56.6M
Total Assets
BBAI
BBAI
GYRE
GYRE
Q4 25
$894.5M
$166.1M
Q3 25
$919.8M
$159.4M
Q2 25
$599.4M
$152.6M
Q1 25
$396.3M
$129.8M
Q4 24
$343.8M
$125.4M
Q3 24
$354.1M
$125.2M
Q2 24
$360.9M
$120.9M
Q1 24
$377.6M
$122.0M
Debt / Equity
BBAI
BBAI
GYRE
GYRE
Q4 25
0.17×
Q3 25
0.17×
Q2 25
0.39×
Q1 25
0.51×
Q4 24
Q3 24
1.54×
Q2 24
1.45×
Q1 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBAI
BBAI
GYRE
GYRE
Operating Cash FlowLast quarter
$-21.8M
$-5.6M
Free Cash FlowOCF − Capex
$-22.1M
$-5.8M
FCF MarginFCF / Revenue
-80.9%
-15.5%
Capex IntensityCapex / Revenue
0.9%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.5M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBAI
BBAI
GYRE
GYRE
Q4 25
$-21.8M
$-5.6M
Q3 25
$-9.6M
$4.7M
Q2 25
$-3.9M
$2.1M
Q1 25
$-6.7M
$-129.0K
Q4 24
$-14.8M
$-2.8M
Q3 24
$-1.9M
$1.7M
Q2 24
$-7.1M
$-5.5M
Q1 24
$-14.4M
$2.9M
Free Cash Flow
BBAI
BBAI
GYRE
GYRE
Q4 25
$-22.1M
$-5.8M
Q3 25
$-9.8M
$4.0M
Q2 25
$-3.9M
$1.8M
Q1 25
$-6.7M
$-251.0K
Q4 24
$-15.0M
$-2.8M
Q3 24
$-2.0M
$1.0M
Q2 24
$-7.2M
$-6.9M
Q1 24
$-14.4M
$2.7M
FCF Margin
BBAI
BBAI
GYRE
GYRE
Q4 25
-80.9%
-15.5%
Q3 25
-29.5%
13.1%
Q2 25
-11.9%
6.8%
Q1 25
-19.4%
-1.1%
Q4 24
-34.2%
-10.1%
Q3 24
-4.9%
4.1%
Q2 24
-18.1%
-27.5%
Q1 24
-43.5%
9.8%
Capex Intensity
BBAI
BBAI
GYRE
GYRE
Q4 25
0.9%
0.4%
Q3 25
0.6%
2.2%
Q2 25
0.0%
1.0%
Q1 25
0.2%
0.6%
Q4 24
0.4%
0.2%
Q3 24
0.3%
2.7%
Q2 24
0.3%
5.8%
Q1 24
0.1%
0.9%
Cash Conversion
BBAI
BBAI
GYRE
GYRE
Q4 25
Q3 25
-3.80×
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons